Shen L, Shah A M, Dahlbäck B, Nelsestuen G L
Department of Clinical Chemistry, Malmö General Hospital and University of Lund, Malmö, Sweden.
Biochemistry. 1997 Dec 23;36(51):16025-31. doi: 10.1021/bi971730v.
Bovine and human protein C show high homology in the amino acids of their GLA domains (amino-terminal 44 residues), despite the about 10-fold higher membrane affinity of the human protein. A proposed membrane contact site and mechanism suggested that this difference was largely due to the presence of proline at position 10 of bovine protein C versus histidine at position 10 of human protein C [McDonald, J.F., Shah, A.M., Schwalbe, R.A., Kisiel, W., Dahlback, B., and Nelsestuen, G.L. (1997) Biochemistry, 36, 5120-5127]. This study examined the impact of replacing proline-10 in bovine protein C with histidine, and the reverse change in human protein C. In both cases, the protein containing proline-10 showed lower membrane affinity, about 10-fold lower for bovine protein C and 5-fold lower for human protein C. As expected, activated human protein C (hAPC) containing proline at position 10 showed 2.4-3.5-fold lower activity than wild type hAPC, depending on the assay used. Most interesting was that bovine APC containing histidine-10 displayed up to 15-fold higher activity than wild type bAPC. This demonstrated the ability to improve both membrane contact and activity by mutation. This general strategy should be applicable to other vitamin K-dependent proteins, providing opportunities to study function as well as to produce proteins that may find use as promoters and inhibitors of blood coagulation in pathological states.
牛蛋白C与人蛋白C的GLA结构域(氨基末端44个残基)的氨基酸具有高度同源性,尽管人蛋白的膜亲和力约高10倍。一种提出的膜接触位点和机制表明,这种差异主要是由于牛蛋白C第10位是脯氨酸,而人蛋白C第10位是组氨酸[麦克唐纳,J.F.,沙阿,A.M.,施瓦尔贝,R.A.,基西尔,W.,达尔巴克,B.,和内尔塞斯图恩,G.L.(1997年)《生物化学》,36,5120 - 5127]。本研究考察了将牛蛋白C中的脯氨酸 - 10替换为组氨酸以及人蛋白C进行反向替换的影响。在这两种情况下,含有脯氨酸 - 10的蛋白显示出较低的膜亲和力,牛蛋白C低约10倍,人蛋白C低5倍。正如预期的那样,第10位含有脯氨酸的活化人蛋白C(hAPC)的活性比野生型hAPC低2.4 - 3.5倍,这取决于所使用的测定方法。最有趣的是,第10位含有组氨酸的牛APC的活性比野生型bAPC高多达15倍。这证明了通过突变改善膜接触和活性的能力。这种通用策略应该适用于其他维生素K依赖性蛋白,为研究功能以及生产可能在病理状态下用作凝血促进剂和抑制剂的蛋白提供了机会。